• Todd Hudnall Joins the Team

    RxStrategies, Inc. is pleased to announce the appointment of Todd Hudnall to the new position of Sales Manager – Midwest Region. He joins the RxStrategies sales team and has responsibility for sales and delivery of customized 340B pharmacy administration and split billing solutions to providers located in the Midwest Region. “I am very pleased to… Read more »

  • 340B Insider – March 2016

    Welcome to the March edition of RxStrategies 340B Insider, a concise communication to provide a quick highlight of updates from RxStrategies’ view. 340B UNIVERSITY UPDATES Recently, the RxStrategies experts attended 340B University, presented by Apexus, to gain further insight regarding current 340B trends.  The following are highlights from a recent session: 1.) 340B Mega Guidance: Over 1300… Read more »

  • RxStrategies Appoints Sales Manager – Northeast Region

    BOCA RATON, Florida, March 3, 2016 – RxStrategies, Inc. is pleased to announce the appointment of Russell Crane to the new position of Sales Manager – Northeast Region. He joins the RxStrategies’ sales team and has responsibility for sales and delivery of customized 340B pharmacy administration and split billing solutions to providers located in the… Read more »

  • Proud Pinnacle Leader Sponsor of the 12th Annual 340B Coalition Winter Conference

    The best way to stay abreast of 340B happenings is to attend the12th Annual 340B Coalition Winter Conference, taking place February 17 to 19 in San Diego, CA. During the conference our team will network with industry leaders to discuss HRSA’s proposed mega-guidance and gain further insight on issues impacting the overall market. Learn more. RxStrategies is proud to… Read more »

  • December 340B Insider

    Welcome to the December edition of RxStrategies 340B Insider, a concise communication to provide a quick highlight of updates from RxStrategies’ view.   Highlights from ASHP Midyear Clinical Meeting This month, the RxStrategies’ team was pleased to participate in ASHP’s Midyear Clinical Meeting and Exhibition, one of the largest gatherings of pharmacists in the world. A Few… Read more »

  • RxStrategies Clinical Insights — November Issue 1

    Welcome to the first November edition of RxStrategies Clinical Insights, designed to help pharmacy professionals stay up to date on the ever-changing pharmaceutical and pharmacy market place.   New Drug Approval Imlygic™ (talimogene laherparepvec) October 27, 2015 — The U.S. Food and Drug Administration approved Imlygic™ (talimogene laherparepvec), the first FDA-approved oncolytic virus therapy, for the… Read more »

  • RxStrategies, Inc. Names Skip Devanny Chief Revenue Officer

    BOCA RATON, Fla., October 28, 2015—RxStrategies, Inc. (www.rxstrategies.com) is pleased to announce the appointment of Skip Devanny to the position of Chief Revenue Officer. In this new role, Skip joins the RxStrategies’ senior leadership team and has responsibility for sales and marketing including the delivery of customized 340B pharmacy administration and split billing solutions to the growing 340B marketplace. “I… Read more »

  • RxStrategies Clinical Insights — October Issue 1

    Welcome to the first October edition of RxStrategies Clinical Insights, designed to help pharmacy professionals stay up to date on the ever-changing pharmaceutical and pharmacy market place.   New Drug Approval Tresiba® (insulin degludec injection) September 25, 2015 — The U.S. Food and Drug Administration approved Tresiba® (insulin degludec injection) and Ryzodeg® 70/30 (insulin degludec/insulin… Read more »

  • RxStrategies Clinical Insights — September 2015 Issue 1

    Welcome to the first September edition of RxStrategies Clinical Insights, designed to help pharmacy professionals stay up to date on the ever-changing pharmaceutical and pharmacy market place.   New Drug Approval Xuriden™ (uridine triacetate) September 4, 2015 — The U.S. Food and Drug Administration approved Xuriden™ (uridine triacetate), the first FDA-approved treatment for patients with… Read more »